Valuation : Fennec Pharmaceuticals Inc.

Market Cap 434M 374M 352M 321M 601M 41.02B 603M 4.16B 1.61B 21.05B 1.63B 1.6B 67.8B P/E 2026 *
38.4x
P/E 2027 * 12.5x
Enterprise Value 434M 374M 352M 321M 601M 41.02B 603M 4.16B 1.61B 21.05B 1.63B 1.6B 67.8B EV / Sales 2026 *
5.96x
EV / Sales 2027 * 4.21x
Free-Float
80.61%
Yield 2026 *
-
Yield 2027 * -
1 day-1.27%
1 week+0.98%
Current month+0.32%
1 month+22.55%
3 months+35.26%
6 months+51.10%
Current year+60.91%
1 week 11.87
Extreme 11.87
12.79
1 month 10.42
Extreme 10.425
13.25
Current year 5.65
Extreme 5.65
13.25
1 year 5.65
Extreme 5.65
13.25
3 years 3.96
Extreme 3.96
13.25
5 years 3.82
Extreme 3.8219
13.25
10 years 1.64
Extreme 1.6439
14.99
Manager TitleAgeSince
Chief Executive Officer 64 16/08/2024
Director of Finance/CFO 51 06/01/2010
Chief Tech/Sci/R&D Officer 51 28/10/2024
Director TitleAgeSince
Director/Board Member 72 25/08/2011
Chairman 69 09/12/2015
Director/Board Member 70 10/08/2016
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell -10,000 0.0288%
31/08/26 Free

Chief Technology Officer

12,168 0.0350%
31/08/26 Free

Executive/Senior Manager

168 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%+0.98%+34.97%+48.03% 434M
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -1.02%+1.08%+28.96%+50.82% 367.88B
Weighted average by Cap. -1.10%+0.55%+36.62%+66.22%

Financials

2026 *2027 *
Net sales 72.9M 62.73M 59.02M 53.92M 101M 6.88B 101M 697M 271M 3.53B 274M 268M 11.38B 103M 88.76M 83.51M 76.29M 143M 9.74B 143M 987M 383M 5B 387M 379M 16.1B
Net income 11.25M 9.68M 9.1M 8.32M 15.56M 1.06B 15.6M 108M 41.75M 545M 42.23M 41.31M 1.76B 35.24M 30.32M 28.53M 26.06M 48.75M 3.33B 48.88M 337M 131M 1.71B 132M 129M 5.5B
Net Debt - -
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
04/09/26 $12.39 -1.27% 212,438
03/09/26 $12.55 +1.95% 296,104
02/09/26 $12.31 +2.33% 292,041
01/09/26 $12.03 -2.59% 348,051
31/08/26 $12.35 +0.65% 508,684
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.39USD
Average target price
17.67USD
Spread / Average Target
+42.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FENC Stock